FDA Mulls Skipping Approvals for Radiology AI Aids
Published Date: 12/29/2025
Notice
Summary
The FDA is considering letting some radiology software devices skip the usual premarket approval process to speed up their availability. This affects companies making computer-aided detection, diagnosis, triage, and notification tools used in medical imaging. If approved, it could save time and money, and the public can comment on this change until February 27, 2026.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Petition to Exempt Radiology AI From 510(k)
The FDA received a petition asking that certain radiology software — including radiological computer-assisted diagnostic software for lesions suspicious of cancer (21 CFR 892.2060, product code POK), medical image analyzers (21 CFR 892.2070, product code MYN), radiological computer-aided triage and notification software (21 CFR 892.2080, product codes QAS and QFM), and radiological computer-assisted detection and diagnosis software (21 CFR 892.2090, product codes QBS and QDQ) — be partially exempt from the 510(k) premarket notification when specific conditions are met. The petition’s conditions include that the manufacturer previously obtained a 510(k) (with device-specific clearance rules for the listed sections), implementation of a robust post-market plan plus transparency and training measures, and that existing special controls, quality systems, establishment registration, and device listing requirements remain in force. Comments on the petition are due by February 27, 2026.
Statutory Timelines Could Auto-Grant Petition
Under the FD&C Act and the 21st Century Cures Act process cited in the notice, FDA must publish an order with its final determination within 120 days after this notice; if FDA fails to respond to a petition within 180 days of receiving it, the petition is deemed granted. Interested parties may submit comments through February 27, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-23900, Environmental Management Site-Specific Advisory Board, Northern New Mexico
The Northern New Mexico Environmental Management Advisory Board is holding a virtual meeting on January 21, 2026, to talk about cleaning up and managing local environmental and nuclear waste sites. This meeting is open to the public, letting community members share their thoughts and stay informed about important cleanup efforts. No money changes are announced, but it’s a key chance for locals to get involved and hear updates.
Next: 2025-23902, Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Update a Definition and Certain Provisions Related to Components of GSD's Funds-Only Settlement
The Fixed Income Clearing Corporation (FICC) is updating some rules about how it handles cash settlements for government securities. They’re changing a key definition, switching some interest payments from daily to monthly, and cleaning up old language. These changes affect financial firms using FICC’s services and take effect immediately, aiming to make money handling smoother and clearer.